ObvioHealth

New York, New York, USA · ≈60 employees · obviohealth.com

ObvioHealth is an enterprise SaaS company that offers a no-code, AI-native platform for decentralized clinical trials (DCT). Founded in 2017 and headquartered in New York, the company has expanded its operations globally, with offices in Singapore, London, Brisbane, and Switzerland. ObvioHealth transitioned to an enterprise SaaS model in 2024 with the launch of ObvioGo 2.0, its flagship platform designed to streamline the execution of virtual and hybrid clinical trials. The ObvioGo platform integrates study design, oversight, and participant engagement into a single system. It supports decentralized trials and hybrid models, enabling electronic patient-reported outcomes (ePRO/eCOA), eConsent, and mobile-first trial designs. The platform adheres to industry standards, ensuring compliance with regulations such as 21 CFR Part 11 and GDPR. ObvioHealth serves a diverse range of clients in the life sciences sector, including pharmaceutical companies, CROs, medical device firms, and academic institutions, across various therapeutic areas. The company's mission is to enhance clinical trial accessibility and efficiency, ultimately accelerating the delivery of life-improving innovations.